摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-methyl-6,7-dihydro[1,3]thiazolo[3,2-a][1,2,3]triazolo[4,5-d]pyrimidin-9(1H)-one

中文名称
——
中文别名
——
英文名称
7-methyl-6,7-dihydro[1,3]thiazolo[3,2-a][1,2,3]triazolo[4,5-d]pyrimidin-9(1H)-one
英文别名
12-Methyl-10-thia-1,4,5,6,8-pentaazatricyclo[7.3.0.0^{3,7}]dodeca-3(7),4,8-trien-2-one;12-methyl-10-thia-1,4,5,6,8-pentazatricyclo[7.3.0.03,7]dodeca-3,6,8-trien-2-one
7-methyl-6,7-dihydro[1,3]thiazolo[3,2-a][1,2,3]triazolo[4,5-d]pyrimidin-9(1H)-one化学式
CAS
——
化学式
C7H7N5OS
mdl
——
分子量
209.231
InChiKey
WBHQTBNEJTXXLN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    99.5
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    1,2-二溴丙烷5-硫代-2,3-二氢三唑并[4,5-e]嘧啶-7-酮三乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 1.0h, 以96%的产率得到7-methyl-6,7-dihydro[1,3]thiazolo[3,2-a][1,2,3]triazolo[4,5-d]pyrimidin-9(1H)-one
    参考文献:
    名称:
    2-(Benzimidazol-2-yl)quinoxalines:  A Novel Class of Selective Antagonists at Human A1 and A3 Adenosine Receptors Designed by 3D Database Searching
    摘要:
    The Cambridge Structural Database (CSD) was searched through two 3D queries based on substructures shared by well-known antagonists at the A(1) and A(3) adenosine receptors (ARs). Among the resulting 557 hits found in the CSD, we selected five compounds to purchase, synthesize, or translate synthetically into analogues better tailored to interact with the biological targets. Binding experiments using human ARs showed that four out of five tested compounds turned out to be antagonists at the A(1)AR or A(3)AR with K-i values between 50 and 440 nM. Lead optimizations of 2-(benzimidazol-2-yl)quinoxalines (BIQs, 3) gave the best results in terms of potency and selectivity at the A(1) and A(3) ARs. Particularly, 2-(4-etliylthiobenzimidazol-2-yl)quinoxaline (3e) exhibited K-i values at the A(1)AR, A(2A)AR, and A(3)AR, of 0.5, 3440, and 955 nM, respectively, whereas 2-(4-methylbenzimidazol-2-yl)quinoxaline (3b) displayed at the same ARs K-i values of 8000, 833, and 26 nM, respectively.
    DOI:
    10.1021/jm050792d
点击查看最新优质反应信息

文献信息

  • 2-(Benzimidazol-2-yl)quinoxalines:  A Novel Class of Selective Antagonists at Human A<sub>1</sub> and A<sub>3</sub> Adenosine Receptors Designed by 3D Database Searching
    作者:Ettore Novellino、Barbara Cosimelli、Marina Ehlardo、Giovanni Greco、Manuela Iadanza、Antonio Lavecchia、Maria Grazia Rimoli、Annalisa Sala、Antonio Da Settimo、Giampaolo Primofiore、Federico Da Settimo、Sabrina Taliani、Concettina La Motta、Karl-Norbert Klotz、Daniela Tuscano、Maria Letizia Trincavelli、Claudia Martini
    DOI:10.1021/jm050792d
    日期:2005.12.1
    The Cambridge Structural Database (CSD) was searched through two 3D queries based on substructures shared by well-known antagonists at the A(1) and A(3) adenosine receptors (ARs). Among the resulting 557 hits found in the CSD, we selected five compounds to purchase, synthesize, or translate synthetically into analogues better tailored to interact with the biological targets. Binding experiments using human ARs showed that four out of five tested compounds turned out to be antagonists at the A(1)AR or A(3)AR with K-i values between 50 and 440 nM. Lead optimizations of 2-(benzimidazol-2-yl)quinoxalines (BIQs, 3) gave the best results in terms of potency and selectivity at the A(1) and A(3) ARs. Particularly, 2-(4-etliylthiobenzimidazol-2-yl)quinoxaline (3e) exhibited K-i values at the A(1)AR, A(2A)AR, and A(3)AR, of 0.5, 3440, and 955 nM, respectively, whereas 2-(4-methylbenzimidazol-2-yl)quinoxaline (3b) displayed at the same ARs K-i values of 8000, 833, and 26 nM, respectively.
查看更多

同类化合物

阿扎次黄嘌呤 钠2-氨基-6-甲基-[1,2,4]三唑并[1,5-a]嘧啶-5-醇 替格瑞洛 曲匹地尔 异亚丙基替卡格雷 布美地尔 唑嘧菌胺 唑嘧磺草胺 去羟基乙氧基替格雷洛 化合物 T15173 v-三唑并[4,5-d]嘧啶,(3H),3-环戊基-7-偏基硫代- [[[3-(4,7-二氢-7-氧代-1H-1,2,3-三唑并[4,5-d]嘧啶-5-基)-4-丙氧基苯基]氨基]亚甲基]丙二酸二乙酯 [1,2,4]噻唑并[1,5-c]嘧啶-5(6h)-酮 [1,2,4]三氮唑并[1,5-A]嘧啶-2-胺 [1,2,4]三唑并[3,4-f]嘧啶 [1,2,4]三唑并[1,5-A]嘧啶-2-羧酸甲酯 [1,2,4]三唑并[1,5-A]嘧啶-2-羧酸 [1,2,4]三唑[1,5,A]嘧啶-7-氨基 [(1R,3S)-3-(5-氨基-7-氯-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)环戊基]甲醇 [(1R,3S)-3-(5,7-二氨基-3H-[1,2,3]三唑并[4,5-d]嘧啶-3-基)环戊基]甲醇 N-甲基-1H-1,2,3-三唑并[4,5-d]嘧啶-7-胺 N-(4'-氟丁酰苯)-4-(4-氯苯基)吡啶正离子 N-(2,6-二氯苯基)-5,7-二甲基[1,2,4]三唑并[1,5-a]嘧啶-2-磺酰胺 N-(2,6-二氯-3-甲苯基)-5,7-二甲氧基-[1,2,4]三唑[1,5-a]嘧啶-2-磺酰胺 N-(2,6-二氯-3-甲基苯基)-5,7-二氯-1,2,4-三唑并[1,5-a]吡啶-2-磺酰胺 N-(1,5,6,7-四氢-3,6-二甲基-5,7-二氧代-1,2,4-三唑并[4,3-c]嘧啶-8-基)-乙酰胺 EED抑制剂(EEDINHIBITOR-1) 9H-7,8-二氢-(1,2,3)三唑并(4',5'-4,5)嘧啶并(6,1-b)(1,3)噻嗪-5(3H)-酮 9-乙基-2,4,7,8,9-五氮杂双环[4.3.0]壬-1,3,5,7-四烯-3,5-二胺 8-甲氧基-3-甲基-[1,2,4]三唑并[4,3-C]嘧啶 8-甲基-1,3,7,9-四氮杂双环[4.3.0]壬-2,4,6,8-四烯 8-溴-[1,2,4]三唑并[4,3-c]嘧啶 8-溴-5-(甲硫基)[1,2,4]三唑并[4,3-c]嘧啶 8-氮鸟嘌呤 8-氮杂黄嘌呤 8-氮杂腺嘌呤 8-氮杂-2,6-二氨基嘌呤硫酸盐 8-乙氧基-5-甲氧基[1,2,4]三唑并[1,5-c]嘧啶-2-胺 8-乙基-4-甲基-1,3,7,9-四氮杂双环[4.3.0]壬-2,4,6,8-四烯 7H-[1,2,3]三唑并[4,5-d]嘧啶 7-(2-呋喃基)[1,2,4]三唑并[1,5-a]嘧啶-2-基胺 7-羟基-5-甲基-2(甲硫基)-1,2,4-三唑并[1,5-a]嘧啶-6-羧酸乙酯 7-羟基-5-甲基-1,3,4-三氮吲哚利嗪 7-甲基[1,2,4]三唑并[4,3-A]嘧啶-3-羧酸 7-甲基[1,2,4]三唑并[1,5-a]嘧啶-5-醇 7-甲基-[1,2,4]噻唑并[4,3-c]嘧啶 7-甲基-8-丙基-[1,2,4]噻唑并[1,5-c]嘧啶 7-环丙基[1,2,4]三唑[1,5-a]嘧啶-2-胺 7-氯-[1,2,4]噻唑并[1,5-c]嘧啶 7-氯-[1,2,4]噻唑并[1,5-a]嘧啶